KIKei Ihira

Kei Ihira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kei Ihira has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer

    by Mika Okazawa-Sakai, Takao Fujisawa, Tatsuyuki Chiyoda, Hiroshi Yagi, Ichinosuke Hyodo, Shogen Boku, Yoh Hayasaki, Masanori Isobe, Daisuke Shintani, Kosei Hasegawa, et al.

    Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11


  • Open Access

    Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer

    by Mika Okazawa-Sakai, Shunsuke A. Sakai, Ichinosuke Hyodo, Satoshi Horasawa, Kentaro Sawada, Takao Fujisawa, Yasuko Yamamoto, Shogen Boku, Yoh Hayasaki, Masanori Isobe, et al.

    Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38


  • Patterns and predictors of site‐specific recurrence in cervical cancer after radical hysterectomy

    by Tatsuya Kato, Chisa Shimada, Fumi Kato, Hiromi Okada‐Kanno, Mahito Takeda, Daisuke Endo, Kei Ihira, Takashi Mitamura, Yosuke Konno, Noriaki Sakuragi, et al.

    Aim: This study examines patterns and predictors of site‐specific recurrence to explore the causes of local recurrence of cervical cancer.Methods: Radical hysterectomy was performed in 121 patients (stage IB–IIB). Nerve‐sparing was performed whenever possible. The first recurrence in local, regional, and distant areas was examined. We investigated the possibility of nerve involvement in local recurrence, focusing on paravaginal tissues containing the pelvic plexus. We provide Supporting Information on local recurrence in the paravaginal area.Results: Local recurrence was an independent event from regional or distant recurrence. Local recurrence was seen only in high‐risk patients, while regional and distant recurrences were not or less related to the risk category. The independent risk factors by logistic regression for local, regional, and distant recurrence were parametrial invasion, vaginal invasion, and lymph node metastasis, respectively. Local recurrence showed a comparable or more significant negative impact on survival than distant recurrence. Among seven patients with local recurrences, five had a recurrence in the paravagina. The rate of paravaginal recurrence was one in 76 early‐stage and four in 45 locally advanced diseases. Four sites of paravaginal recurrence occurred on the nerve‐sparing side and two on the non‐nerve‐sparing side. Supporting Information demonstrated histological evidence of perineural spread into the pelvic plexus and perineural invasion of the primary tumor.Conclusions: A high percentage of local recurrences are in paravaginal tissue containing the pelvic plexus. The causal association of nerve‐sparing surgery and perineural invasion with local recurrence needs to be investigated in large prospective studies.


  • Open Access

    Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study

    by Michinori Mayama, Hiroshi Asano, Eiji Nomura, Kei Ihira, Ayako Nozaki, Tatsuya Kato, Yousuke Konno, Takashi Mitamura, Noriko Kobayashi, Mahito Takeda, et al.

    Objective: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles. Methods: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient’s background differences were assessed with inverse probability of treatment weighting using propensity score. Results: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3–4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51–10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455. Conclusion: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.


  • Open Access

    Laparoscopic surgery in osteogenesis imperfecta (OI) patient with tubo-ovarian abscess (TOA): A case report

    by Tomohiro Uda, Masataka Kudo, Yasuhiro Ohara, Hiroyuki Yamazaki, Yasunari Ishizuka, Kei Ihira, Rieko Tanaka, Hidemichi Watari

    総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。